Deliver Therapeutics applies high-throughput DNA encoded library (DEL) screening to discover novel small molecule therapeutics for challenging clinical indications. The company focuses on developing best-in-class inhibitors targeting key tyrosine kinases to overcome cancer resistance mechanisms. Additionally, they are developing senomorphic therapies using selective JAK inhibitors to regulate the senescence-associated secretory phenotype (SASP) in age-related diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Developing novel small molecule therapeutics to address challenging clinical needs, particularly in oncology and age-related diseases, is hindered by the limitations of traditional drug discovery methods. Identifying compounds that are both best-in-class and first-in-class requires advanced screening capabilities to overcome complex biological targets and resistance mechanisms.
Solution
Deliver Therapeutics employs high-throughput DNA Encoded Library (DEL) screening to discover novel small molecule therapeutics. This platform enables the identification of best-in-class and first-in-class compounds targeting difficult clinical challenges. The company's technology focuses on key areas such as kinase inhibition for oncology and the regulation of the Senescence-Associated Secretory Phenotype (SASP) for age-related diseases. By leveraging a library of billions of compounds, Deliver Therapeutics aims to develop differentiated therapeutic candidates with improved efficacy and safety profiles compared to existing treatments.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and academic research institutions seeking to advance novel small molecule therapeutics for oncology and age-related diseases.
Features
- High-throughput DNA Encoded Library (DEL) screening platform for small molecule discovery.
- Identification of novel pharmacophores with high affinity (low nM IC50s) against challenging targets.
- Development of multi-kinase inhibitors targeting key oncogenic drivers, including ABL1 and its resistant mutants (e.g., T315I), BTK, JAK, and SRC family kinases.
- Focus on senomorphic therapies to down-regulate the Senescence-Associated Secretory Phenotype (SASP) by selectively inhibiting JAK kinases, particularly JAK2/3, while avoiding JAK1 inhibition.
- Proprietary DEL screening process utilizing a library of 7 billion compounds.
- Development of a novel multi-kinase inhibitor (DTC-0220) with potential application in Ph+ ALL, Ph-like ALL, and T-ALL.
- Development of selective topical and systemic JAK2/3 inhibitors for senomorphic therapy.